Search research articles
Contact Us
Filters
Showing results (61-70 of 418) with videos related to
Page
of 42
Sort By:
Expert Opinion on Investigational Drugs
|
May 14, 2020
Metastatic melanoma: therapeutic agents in preclinical and early clinical development
Laura Amanda Boos, Isla Leslie, James Larkin
The Lancet. Oncology
|
July 1, 2021
Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis
Ruth Percik, James Larkin, Daniel L Morganstein
Expert Review of Anticancer Therapy
|
December 14, 2021
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma
Andreas M Schmitt, Lucy Dumas, James Larkin
Expert Opinion on Drug Safety
|
May 1, 2015
Safety of pembrolizumab for the treatment of melanoma
Juan Martin-Liberal, Tiana Kordbacheh, James Larkin
The New England Journal of Medicine
|
December 21, 2017
Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Linda Rollin, James Larkin
Therapeutic Advances in Medical Oncology
|
July 7, 2018
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection
Michael Flynn, Lisa Pickering, James Larkin, et al.
Therapeutic Advances in Medical Oncology
|
March 2, 2013
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
Muhammad Khattak, Rosalie Fisher, Samra Turajlic, et al.
BMC Public Health
|
June 15, 2022
Self-rated health and quality of life among Syrian refugees in Ireland - data from a cross-sectional study
Claire Collins, Ivana Pericin, James Larkin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 1, 2017
Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features
Lavinia Spain, Thomas Schmid, Martin Gore, et al.
Cancer Communications (London, England)
|
October 15, 2025
Tumor-infiltrating lymphocyte therapy and the mucosal melanoma treatment landscape
Jennifer Thomas, Max Julve, James Larkin, et al.
Page
of 42
Search research articles
Search
Showing results (61-70 of 418) with videos related to
Sort By:
Page
of 42
Expert Opinion on Investigational Drugs
|
May 14, 2020
Metastatic melanoma: therapeutic agents in preclinical and early clinical development
Laura Amanda Boos, Isla Leslie, James Larkin
The Lancet. Oncology
|
July 1, 2021
Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis
Ruth Percik, James Larkin, Daniel L Morganstein
Expert Review of Anticancer Therapy
|
December 14, 2021
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma
Andreas M Schmitt, Lucy Dumas, James Larkin
Expert Opinion on Drug Safety
|
May 1, 2015
Safety of pembrolizumab for the treatment of melanoma
Juan Martin-Liberal, Tiana Kordbacheh, James Larkin
The New England Journal of Medicine
|
December 21, 2017
Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Linda Rollin, James Larkin
Therapeutic Advances in Medical Oncology
|
July 7, 2018
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection
Michael Flynn, Lisa Pickering, James Larkin, et al.
Therapeutic Advances in Medical Oncology
|
March 2, 2013
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
Muhammad Khattak, Rosalie Fisher, Samra Turajlic, et al.
BMC Public Health
|
June 15, 2022
Self-rated health and quality of life among Syrian refugees in Ireland - data from a cross-sectional study
Claire Collins, Ivana Pericin, James Larkin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 1, 2017
Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features
Lavinia Spain, Thomas Schmid, Martin Gore, et al.
Cancer Communications (London, England)
|
October 15, 2025
Tumor-infiltrating lymphocyte therapy and the mucosal melanoma treatment landscape
Jennifer Thomas, Max Julve, James Larkin, et al.
Page
of 42